Janice K. Brewer , Governor Anthony D. Rodgers, Director 801 East Jefferson, Phoenix AZ 85034 phone 602 417 4000 Our first care is your health care ARIZONA HEALTH CARE COST CONTAINMENT SYSTEM Prior Authorization Protocol Therapeutic Class: Smoking Cessation Aids Formulary Status: Medication Classes: Nicotine Patch - Nicoderm CQ , Nicotrol , Habi
- A |
J |K |
U |V |
Conversely, injection forms, though being painful and needing help of medical personnel for application, help to quickly achieve necessary concentration of preparation in blood doxycycline online Antibiotic is usually chosen in an empiric way (at random). But when choosing one is obligatory guided by definite rules.
Microsoft word - mrsa on the rise06-07.doc(Methicillin -Resistant Staphylococcus Aureus)
Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium that causes
infections in the body. MRSA infection is an infection with a strain of Staphylococcus
aureus bacteria that is resistant to antibiotics known as beta-lactams.1 These commonly
used antibiotics include methicillin, amoxicillin, and penicillin.
Most MRSA infections occur in people with weak immune systems, usually patients in
hospitals and long- term care facilities. MRSA infections in hospitalized patients are
known as healthcare-associated (HA-MRSA).1 MRSA infections in people not
considered high-risk in the community are known as community-associated MRSA (CA-
MRSA).1 Poor hygiene, crowded living conditions, athletes who share equipment,
prisoners, and children in daycare facilities are considered risk factors for MRSA.
Unfortunately, there has been a recent increase of both community and hospital
acquired MRSA. Some have speculated that the increase may be due to the
inappropriate use of third-generation cephalosporins,2 while others suggested
widespread use of quinolones is responsible.3
The standard laboratory gram-positive susceptibility testing panels list vancomycin and
linezolid as antibiotics to which MRSA is sensitive.4 Vancomycin has long been
considered the gold standard for treating MRSA infections because vancomycin-
resistant staphylococci are rare.4 Unfortunately, when vancomycin is used as single
drug therapy to treat MRSA infections, cure rates in serious infections has been very
disappointing (avg.40% failure).4 In treating nonserious MRSA infections, such as
wound, skin and urinary tract infections (UTIs), in addition to slow cure rates and failure
vancomycin is practically and economically burdensome. Because there is no oral form,
a patient for whom vancomycin is prescribed must be infused (IV or infusaport).
Additionally, to avoid toxicity, blood levels must be monitored regularly. Linezolid, an oral
drug that most MRSA isolates test sensitive carries a risk of hematological
abnormalities, including myclosuppression and thrombocytopenia.4 Linezolid, like
vancomycin, is extremely economically burdensome. So in response to alternatives to
vancomycin and linezolid new approaches are being investigated.
One option for clinicians to consider is rifampin combination therapy; if the patient has
a serious staphylococcal infection.4 Although rifampin is ineffective as a single-drug
therapy for treating staph infections, numerous studies have shown that when rifampin is
combined with vancomycin, trimethoprin-sulfamethoxazole, mineocycline, or
ciprofloxacin the clinical outcomes are markedly improved.4
Unfortunately, no treatment guarantees clinical success. This article in no way is
recommending a specific treatment , rather it is hoped this material will prompt
discussions and awareness among the medical community that will in some small way
improve patient care and lessen resistant staphylococci.
“MRSA infection” ,www.nlm.nih.gov/medlineplus/ency/article/007261, updated by Kenneth Wener M.D. Fukatsu K, Saito H, Matsuda T, Ikeda S, Furukawa S, Muto T, influences of type & duration of antimicrobial Prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus and on the incidence of wound infection. Arch Surg Dec.1997, 132-11320-1325 Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmel Y, Fluoroquinolones and the risk for MRSA is hospitalized patients, Emerg Infect Dis. November 2003,9:1415-1422 “ No mercy for MRSA” Medical Laboratory Observer by Dennis L. Wegner PhD Jan 2005 pg 26-29
A N N A L S O F T H E N E W Y O R K A C A D E M Y O F S C I E N C E SIssue: Cooley’s Anemia: Ninth Symposium Treatment options for thalassemia patients with osteoporosis Evangelos Terpos1 and Ersi Voskaridou21Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece. 2Thalassemia Center, LaikonGeneral Hospital, Athens, GreeceAddress for correspondence: Evan